文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

琥珀酰明胶与氨基酸输注减少放射性标记αvβ6整合素靶向肽肾脏摄取的效果:临床安全性考量

Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-05-08

研究在正常及荷瘤小鼠中比较琥珀酰明胶(gelo)与精氨酸/赖氨酸(Arg/Lys)对68Ga-Trivehexin和177Lu-D0301肾脏摄取的抑制作用。Gelo使肾脏摄取降低61%–85%,优于Arg/Lys的25%–41%,且肿瘤/肾脏比值提高约2.6–3.3倍;作者认为在类似对比剂风险管理下,gelofusine用于放射配体治疗临床可行。

要点

  • Gelo使177Lu-D0301肾脏摄取降低61%–85%,Arg/Lys仅降低25%–41%。
  • Gelo使荷瘤小鼠肿瘤/肾脏比值提高3.3倍(90分钟)和2.6倍(24小时)。
  • 琥珀酰明胶严重不良事件(过敏反应)发生率与钆/碘对比剂相当。

核心结论

  • Gelofusine对两种放射性药物的肾脏摄取抑制效果优于Arg/Lys,使肿瘤/肾脏比值提高约三倍。
  • 作者认为,若采用与对比剂类似的风险管理策略,gelofusine用于放射配体治疗的临床使用似乎是可行的。

研究设计与样本

  • 在健康C57BL/6N小鼠和H2009人肺腺癌异种移植CB17-SCID小鼠中行离体生物分布测定。
  • 68Ga-Trivehexin于注射后90分钟测定,177Lu-D0301于注射后90分钟和24小时测定。
  • 比较未干预与共输注100 µL含2.5%精氨酸+2.5%赖氨酸(Arg/Lys)、4%琥珀酰明胶(gelo)或其组合的溶液。
  • Arg/Lys于放射性药物前30分钟和后30分钟腹腔注射,或于放射性药物前2分钟静脉注射;gelo于放射性药物前2分钟静脉注射或预混后与放射性药物一同注射(每组n=5)。
  • C57BL/6N小鼠另行PET(注射后90分钟)和SPECT(注射后24小时)显像。

主要发现

  • C57BL/6N小鼠中,68Ga-Trivehexin注射后90分钟肾脏摄取较对照降低15%(Arg/Lys腹腔注射)、25%(Arg/Lys静脉注射)和70%(gelo静脉注射)。
  • 177Lu-D0301注射后24小时肾脏摄取较对照降低2%(Arg/Lys腹腔注射)、41%(Arg/Lys静脉注射)、61%(gelo静脉注射)和66%(gelo+Arg/Lys静脉注射)。
  • Arg/Lys与gelo联用未提供实质性额外获益。
  • H2009荷瘤SCID小鼠中,gelo使177Lu-D0301肾脏摄取降低76%(注射后90分钟)和85%(注射后24小时)。
  • 肿瘤摄取在注射后90分钟未降低,注射后24小时仅轻微降低15%,肿瘤/肾脏比值提高3.3倍(注射后90分钟)和2.6倍(注射后24小时)。

关键数值与推荐

  • Gelofusine使肾脏摄取降低61%–85%,Arg/Lys降低25%–41%。
  • 琥珀酰明胶产品严重不良事件(过敏反应)报告发生率为0.0062%–0.038%,钆对比剂为0.008%,碘对比剂为0.04%。

临床怎么用

  • 作者认为,在采用与对比剂类似的风险管理策略下,gelofusine用于放射配体治疗的临床使用似乎是可行的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 68Ga-Trivehexin is an investigational PET radiopharmaceutical (NCT05799274) targeting αvβ6-integrin for PET imaging of carcinomas. 177Lu-D0301 is a structurally related therapeutic peptide tetramer. However, it showed considerable kidney uptake in rodents, impeding clinical applicability. We therefore evaluated the impact of different kidney protection strategies on the biodistribution of both agents in normal and tumor-bearing mice. METHODS: Ex-vivo biodistribution of 68Ga-Trivehexin (90 min p.i.) and 177Lu-D0301 (90 min and 24 h p.i.) was determined in healthy C57BL/6N and H2009 (human lung adenocarcinoma) xenografted CB17-SCID mice without and with co-infusion of 100 µL of solutions containing 2.5% arginine + 2.5% lysine (Arg/Lys), 4% succinylated gelatin (gelofusine, gelo), or combinations thereof. Arg/Lys was injected either i.p. 30 min before and after the radiopharmaceutical, or i.v. 2 min before the radiopharmaceutical. Gelo was administered either i.v. 2 min prior activity, or pre-mixed and injected together with the radiopharmaceutical (n = 5 per group). C57BL/6N mice were furthermore imaged by PET (90 min p.i.) and SPECT (24 h p.i.). RESULTS: Kidney uptake of 68Ga-Trivehexin in C57BL/6N mice was reduced by 15% (Arg/Lys i.p.), 25% (Arg/Lys i.v.), and 70% (gelo i.v.), 90 min p.i., relative to control. 177Lu-D0301 kidney uptake was reduced by 2% (Arg/Lys i.p.), 41% (Arg/Lys i.v.), 61% (gelo i.v.) and 66% (gelo + Arg/Lys i.v.) 24 h p.i., compared to control. Combination of Arg/Lys and gelo provided no substantial benefit. Gelo furthermore reduced kidney uptake of 177Lu-D0301 by 76% (90 min p.i.) and 85% (24 h p.i.) in H2009 bearing SCID mice. Since tumor uptake was not (90 min p.i.) or only slightly reduced (15%, 24 h p.i.), the tumor/kidney ratio was improved by factors of 3.3 (90 min p.i.) and 2.6 (24 h p.i.). Reduction of kidney uptake was demonstrated by SPECT, which also showed that the remaining activity was located in the cortex. CONCLUSIONS: The kidney uptake of both investigated radiopharmaceuticals was more efficiently reduced by gelofusine (61-85%) than Arg/Lys (25-41%). Gelofusine appears particularly suitable for reducing renal uptake of αvβ6-integrin targeted 177Lu-labeled peptide multimers because its application led to approximately three times higher tumor-to-kidney ratios. Since the incidence of severe adverse events (anaphylaxis) with succinylated gelatin products (reportedly 0.0062-0.038%) is comparable to that of gadolinium-based MRI or iodinated CT contrast agents (0.008% and 0.04%, respectively), clinical use of gelofusine during radioligand therapy appears feasible if similar risk management strategies as for contrast agents are applied.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Stangl S, Nguyen NT, Brosch-Lenz J, et al. Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles. Eur J Nucl Med Mol Imaging. 2024. PMID: 38717591. doi:10.1007/s00259-024-06738-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。